Home

HCP Resources

Printer-friendly versionSend to friendPDF version
Title Image: 

Our pledge to you and your patients:

low co-pay cost,*† prior-authorization support

 

Resources for your patients

$15 co-pay cap

1. Automatic Rx savings*

  • 65% of pharmacies offer automatic savings, including Walmart, CVS, Walgreens, and Rite Aid
  • No card required. Patients automatically receive up to $200 off every SUMAVEL® DosePro® prescription after they pay a $15 co-pay (minimum of 4 doses per prescription)

Pharmacists requesting help with claim processing should call 1-800-388-2316. Pharmacists enquiring about enrolling in the program should call 1-800-215-9392.

Click here for a list of participating pharmacies.

2. Rx Savings Card†

  • Patients will receive up to $200 off their SUMAVEL DosePro prescription after they pay a $15 co-pay (minimum of 4 doses per prescription)
  • Uninsured patients can receive Sumavel DosePro at a reduced rate of $50 per dose
  • Available from your sales representative or click here to download a coupon
  • Can be used for up to 6 prescription fills

Patients with additional questions about the $15 co-pay card should call 1-877-343-6451, and press zero (0) to speak to a Trial Card associate. Pharmacists with additional questions about the $15 co-pay card should call 1-877-343-6456.

*Eligibility and Restrictions: No claims paid by government-sponsored insurance plans including Medicare, Medicaid, federal, state, or patient pharmaceutical assistance. Patients must be between the ages of 18 and 64. No pharmacies in states that prohibit the offering of co-pay assistance at the point of dispensing (e.g., MA). No cash claims.

†Subject to eligibility. Both insured and noninsured patients are eligible to participate in this program, excluding federal Medicare, Medicaid, and other federal or state-funded programs. Card is void in Massachusetts, except for cash-paying clients. Uninsured patients can receive Sumavel DosePro at a reduced rate of $50 per dose. Patients must be 18 years or older to participate.

 

Resources for your office

Prior-authorization support

SUMAVEL DosePro Support Program—prior-authorization fulfillment services for you and your patients

  • Prior-authorization and reimbursement support
  • Insurance investigation
  • Coordination of product delivery to patient
  • Refill reminders
  • Consultative pharmacist available

The SUMAVEL DosePro Support Program is available 9:00 AM – 7:00 PM, Eastern Time, Monday through Friday. Call our Program Specialist toll-free at 1-888-702-1983 to join or to find out more about the program. Click here to download the Prior Authorization Service Request Form.

INDICATION and IMPORTANT LIMITATIONS

SUMAVEL DosePro (sumatriptan injection) is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.

 

SUMAVEL DosePro is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine and should not be administered intravenously. SUMAVEL DosePro should only be used where a clear diagnosis of migraine or cluster headache has been established. For a given attack, if a patient does not respond to the first dose of SUMAVEL DosePro, the diagnosis of migraine or cluster headache should be reconsidered before administration of a second dose.

IMPORTANT SAFETY INFORMATION

SUMAVEL DosePro is contraindicated in patients with uncontrolled hypertension, in patients with history, symptoms or signs of ischemic heart disease, coronary artery vasospasm, cerebrovascular or peripheral vascular disease including ischemic bowel disease and in patients with other significant underlying cardiovascular diseases or known hypersensitivity to sumatriptan. SUMAVEL DosePro should not be given to patients in whom unrecognized coronary artery disease is predicted by the presence of risk factors without a prior cardiovascular evaluation.

 

Serious cardiovascular events, including death, have been reported when taking sumatriptan, including patients with no findings of cardiovascular disease. Considering the extent of use of sumatriptan in patients with migraine, the incidence of these events is extremely low. Cerebrovascular events, some fatal, have been reported in patients treated with sumatriptan. In a number of cases, it appears possible that the cerebrovascular events were primary, sumatriptan having been administered in the incorrect belief the symptoms experienced were a consequence of migraine when they were not. It is important to advise patients not to administer SUMAVEL DosePro if a headache being experienced is atypical.

 

SUMAVEL DosePro should not be used within 24 hours of other ergotamine-containing or ergot-type medications or other 5-HT1 agonists and is not generally recommended for use with MAO-A inhibitors. The development of a potentially life-threatening serotonin syndrome may occur with triptans, including treatment with SUMAVEL DosePro, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). SUMAVEL DosePro should be used during pregnancy only if the potential benefit justifies the potential risk.

 

In controlled clinical trials with sumatriptan injection, the most common adverse reactions were injection site reactions, tingling, warm/hot sensation, burning sensation, feeling of heaviness, pressure sensation, feeling of tightness, numbness, feeling strange, tight feeling in head, flushing, tightness in chest, discomfort in nasal cavity/sinuses, jaw discomfort, dizziness/vertigo, drowsiness/sedation and headache.

 

By clicking OK, you will leave the SUMAVEL DosePro website. Zogenix, Inc. and Astellas Pharma US, Inc. do not review the information on this website for content, accuracy, completeness or compliance with any applicable statute, rule or regulation.

OK Cancel

The information in this section is intended for healthcare professionals in the United States and is not intended for the general public.

Please confirm below that you are a healthcare professional.

OK Cancel